Original Research Article

Molecular characterization of metallo-beta-lactamase producers among carbapenem resistant *Pseudomonas aeruginosa* isolated from cases of hospital acquired infections in a tertiary care hospital, Bengaluru

Ashwini Sondakar¹, Sneha K Chunchanur², Ambica Rangaiah²,
Sathyanarayan Muthur Shankar^{2,*}

¹Dept. of Microbiology, Belgaum Institute Medical Sciences, Belagavi, Karnataka, India

²Dept. of Microbiology, Bangalore Medical College & Research Institute, Bengaluru, Karnataka, India

ARTICLE INFO

Article history:

Received 04-02-2020

Accepted 13-03-2020

Available online 20-07-2020

Keywords:

Metallobetalactamases

Carbapenemase

Pseudomonas aeruginosa

ABSTRACT

Background: *Pseudomonas aeruginosa* is an important cause of multidrug-resistant nosocomial infections. The knowledge of resistance mechanisms in *Pseudomonas* is an important issue for antimicrobial treatment. Therefore, the objective was to detect carbapenems resistance in *P. aeruginosa* by phenotypic methods and genes (*blaIMP* and *blaVIM*) coding for carbapenemase resistance.

Materials and Methods: The study conducted in the Department of Microbiology, BMCRI, Bengaluru. 91 samples from the patients hospitalised for 48 hours and more were processed. Carbapenem resistant *P. aeruginosa* (CRPA) were identified by biochemical tests and by Kirby Bauer Disk diffusion method as per CLSI guidelines. Those carbapenem resistant isolates were further subjected to two MBL detecting phenotypic tests- Modified Hodge Test (MHT) and Combined disk Test (CDT) by using imipenem and imipenem/ EDTA disk and MBL genes (*blaIMP* and *blaVIM*) were identified by PCR.

Results: 91 clinical isolates were identified as CRPA, 92.3% isolates were positive by CDT whereas only 13.2% of isolates showed positive by MHT method indicating MBL production. Among 91 strains, 19.04% strains were harbouring *blaVIM* and 1.2% strain harbouring *blaIMP* gene.

Conclusion: The detection of MBL-producing *P. aeruginosa* help in appropriate antimicrobial therapy and avoid development and dissemination of these strains. Hence routine detection of MBL production in *P. aeruginosa* should be undertaken. All CRPA isolates should be routinely screened for MBL production using CDT and positive isolates should be confirmed by PCR. MHT test had low sensitivity. To understand the epidemiology, there is a need of genetic analysis and typing of MBL enzymes.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Pseudomonas aeruginosa is a Gram-negative bacterium with the ability to persist in both community and hospital settings. It is an important nosocomial pathogen with emerging resistance to many effective groups of antibiotics through both intrinsic and acquired resistance mechanisms. Carbapenems are the drug of choice for infections caused by *Pseudomonas aeruginosa* including other Gram-negative organisms.¹ Global emergence of

carbapenem resistance *Pseudomonas aeruginosa* (CRPA) including resistance to beta-lactams, Aminoglycosides, and Fluoroquinolones represents an extraordinary threat to public health. The major mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* include carbapenem hydrolyzing enzymes i.e. carbapenemase, decrease outer membrane permeability and alteration penicillin-binding proteins.² However, the clinical use of these antimicrobials is under threat with the emergence of carbapenemases, particularly Metallo- β -lactamases (MBLs).² MBL belongs to Ambler class B, and these enzymes can hydrolyze a wide variety of beta-lactam agents, such as penicillin,

* Corresponding author.

E-mail address: drsathyams@gmail.com (S. M. Shankar).

cephalosporins, and carbapenems. They require zinc for their catalytic activity and are inhibited by metal chelators, such as EDTA and thiol-based compounds.³ MBLs in *P. aeruginosa* were identified in 1991 in Japan⁴ and since then have been described from various parts of the world, including Asia, Europe, Australia, South America, and North America^{4,5} whereas in India *bla_{VIM}*, *bla_{IMP}* and *bla_{NDM}* genes are frequently encountered in *P. aeruginosa*.⁶

The genes responsible for the production of MBLs are typically part of an integron structure and are carried on transferrable plasmids but can also be part of the chromosome.⁷ Due to integron-associated gene cassettes, MBL producing *P. aeruginosa* isolates are often resistant to different groups of antimicrobial agents, which can be transferred to another Gram-negative bacteria.⁸

MBLs in Carbapenem-resistant *Pseudomonas aeruginosa* can be detected by different phenotypic methods and these methods are based on the ability of metal chelators to inhibit the activity of MBLs such as EDTA and thiol-based compounds.⁹ These include Combined Disk Test (CDT)⁹ using EDTA with imipenem (IPM), Modified Hodge test (MHT), MBL Epsilonometer test (E-test) and EDTA disk potentiation test.^{10,11} A PCR detection assay is considered as a gold standard method for the detection of MBL producers.¹² Because of the increasing rate of resistance to the carbapenems, the treatment of infections produced by MBLs producing *P. aeruginosa* is becoming critical.

Hence the present study was undertaken to detect presence of MBLs among Carbapenem-Resistant *Pseudomonas aeruginosa* (CRPA) isolates by phenotypic methods like MHT and Combined Disk Test (CDT) by using Imipenem (IPM)- Ethylene diamine tetraacetic acid (EDTA) and to identify the MBL genes (*bla_{VIM}* and *bla_{IMP}*) coding for carbapenemase resistance by conventional PCR in a tertiary care hospital in Bengaluru.

2. Materials and Methods

This study was conducted over a period of one year from January 2018 to December 2018 at a tertiary hospital, BMCRI, Bengaluru. Ethical clearance was obtained from the institutional ethical committee. This study included 91 non-consecutive clinical samples from patients hospitalized for 48 hours and more, received for culture and sensitivity in the Department of Microbiology.

All the clinical specimens were subjected to direct microscopy, growth on culture media and series of tests for identification of *P. aeruginosa*. These isolates were subjected to antimicrobial susceptibility testing by Kirby-Bauer disk diffusion method according to CLSI guidelines.¹³ The antibiotics tested include amikacin (30µg), ciprofloxacin (5µg), ceftazidime (30µg), piperacillin-tazobactam (100/10µg), imipenem (10µg), meropenem (MEM-10µg), aztreonam (30 µg), colistin (10 µg) and polymyxin-B (300 units). All the disks were obtained

commercially (Hi-Media Laboratories Limited, Mumbai, India). ATCC strain of *Pseudomonas aeruginosa* 27853 is used as control.

All isolates resistant to imipenem or meropenem or ceftazidime or any two of them were considered as probable MBL producer. All positive isolates were further tested by two phenotypic tests for the MBL detection, described as follows.

2.1. Imipenem- Ethylene diamine tetraacetic acid combined disc test

A lawn culture of test isolate was prepared. Allowed to dry for five minutes. Two imipenem (10 µg) discs, one with 0.5 M EDTA and other a plain imipenem disc, were placed on the surface of agar plates approximately 30mm apart. The plates were incubated overnight at 37°C for 16-18h. An increase in zone diameter of >7mm around the imipenem-EDTA disc in comparison to imipenem disk alone indicates the production of MBL.⁹

2.2. Modified Hodge Test (MHT)

A saline suspension of a 0.5 McFarland standard of *E. coli* ATCC 25922 was prepared and diluted 1:10 and lawn inoculated on Muller Hinton Agar (MHA). The plate was allowed to dry for 3-10 minutes. An imipenem (10 µg) disk was placed at the center and 3-5 colonies of test organisms were inoculated in a straight line drawn out from the edge of the disk. A known NDM positive strain was used as Positive control and incubated overnight at 35°C for 20-24h. the presence of a distorted zone of inhibition or cloverleaf type of indentation at the intersection of the test organism and *E. coli*. within the zone of inhibition of the IPM disk was interpreted as a positive result.^{10,11}

2.3. PCR for carbapenem encoding gene

Isolates tested positive in the phenotypic test are subjected to conventional PCR for detection genes coding for MBLs. The DNA extraction was done by the crude method (boiling method). Freshly subcultured colonies were suspended in 50 µl of PCR grade water, heated to 99°C for 10 minutes in a water bath and kept at room temperature for 5 minutes. The suspension is centrifuged at 14000 rpm for 1min at 4°C, 5 µl of supernatant was used as the template for a 50 µl PCR reaction. PCR was performed by using previously designed primers (Sigma-Aldrich, Bengaluru) for *bla_{VIM}*, and *bla_{IMP}* (Table 1)¹⁴

Amplification was performed in 50 µl PCR mixture consisting of master mix (25 µl)- Taq DNA polymerase 2x master mix RED 1.5 mM MgCl₂ (Synergy Scientific Service PVT. LTD), PCR grade water (18µl), Primer *bla_{VIM}*, and *bla_{IMP}* F' and R' (1µl each) and DNA (5µl).

DNA was amplified in a Master cycler Eppendorf under the following conditions (Table 1) and PCR products

were kept at 4°C. Known *bla_{VIM}*, and *bla_{IMP}*, producing laboratory strain *Pseudomonas aeruginosa* was used as the positive control. *Pseudomonas aeruginosa* ATCC 27853 reference strain was used as the MBL gene's negative strain. Cycling conditions for MBL (*bla_{VIM}* and *bla_{IMP}*) gene were described (Table 2).¹²

The PCR products were analyzed by gel electrophoresis with 2% agarose gel in TAE (tris-acetate buffer) buffer with 1.5 µl ethidium bromide and were visualized and photographed under ultraviolet illumination.

3. Results

Among ninety-one CRPA isolates included in the study 70.3% were from the pus, 12.08% from blood and body fluids, 6.5% from urine, 3.3% from respiratory samples and 3.29% from others (Corneal and ENT). Distribution of isolates according to wards as follows, General surgery (42.8%), burns and plastic surgery (27.4%), ICUs (9.8%), orthopedics (4.3%), Nephro-urology (4.3%) and others - ENT and ophthalmic (2.19%).

The antimicrobial susceptibility testing of CRPA isolates showed resistance to other antimicrobials including ceftazidime and cefepime (95.6% each), ciprofloxacin and levofloxacin (91.2% each), piperacillin (94.5%), ticarcillin (96.7%), piperacillin-tazobactam (86.8%), ticarcillin (96.7%), piperacillin-tazobactam (86.8%), amikacin (83.5%), gentamicin (86.8%), aztreonam (80.2%), whereas only 12.08% isolates were resistant to colistin (Figure 1).

Fig. 1: Antimicrobial susceptibility test in Carbapenem resistant *Pseudomonas aeruginosa* (CRPA) isolates. Antimicrobial susceptibility test in carbapenem resistant *Pseudomonas aeruginosa* (CRPA) isolates

3.1. MBL phenotypic screening tests

Among the two phenotypic tests, Combined Disc Test using imipenem and EDTA was positive in 84 isolates and Modified Hodge Test was positive in only 12 isolates. In this study, CDT showed high sensitivity (92.3%) while MHT was least sensitive (13.18%) (Figure 2).

Fig. 2: MBL phenotypic screening tests

3.2. PCR for carbapenem encoding gene

Positively tested isolates by MBL phenotypic screening tests are further confirmed by conventional PCR. Out of 84 isolates, 16 isolates carried *bla_{VIM}* (19.04%) and one isolate carried *bla_{IMP}* gene (1.19%). (Figures 3, 4 and 5)

Fig. 3: MBL genes coding for Carbapenem resistance

Table 1: Primer sequence used in PCR and their product size as follows.¹⁴

Primer	Primer sequence (5'-3')	Product size (base pairs)
bla VIM-F	TTT GGT CGC ATA TCG CAACG	500
bla VIM-R	CCA TTC AGC CAG ATC GGC AT	500
bla IMP-F	GTT TAT GTT CAT ACW TCG	432
bla IMP-R	GGT TTA AYA AAA CAA CCA C (W=A or T; Y=C or T)	432

Table 2: Cycling conditions for different gene identification¹²

Steps in PCR	VIM	IMP
Initial DNA denaturation	940C 5min	940C 5min
Final DNA denaturation	950C 30sec	950C 30sec
Primer annealing	660C 1min	450C 1min
Primer extension	720C 30 sec	720C 26 sec
Final extension or Holding temperature	720C 10 min	720C10 min
Cycles	30	30

Fig. 4: Agarose gel run for blaVIM **Fig. 5:** Agarose gel run for blaIMP

4. Discussion

Antimicrobial resistance is a significant route cause of healthcare-associated infections all over the world. Carbapenem has been used as the last choice of treatment of many Gram-negative organisms. In the current study, we have included carbapenem-resistant *P. aeruginosa* isolates. Carbapenem resistance among Gram-negative bacteria has

been increased in recent years in the Indian subcontinent and MBL producing isolates have emerged worldwide and are associated with outbreaks in health care settings over the past few years.

In this study, most of the carbapenem-resistant *Pseudomonas aeruginosa* isolates were from pus (70.3%) and from general surgery ward (42.8%) and most of them were resistant to other class of antibiotics

such as Anti-pseudomonal Penicillin's, Aminoglycosides, Fluoroquinolones, Cephalosporins, and Aztreonam. This indicates the concomitant presence of other beta-lactamases. Polymyxins showed susceptibility of 87.9% (n=91) which was high compared to other classes of antibiotics and hence considered as a treatment option of CRPA isolates.

In this study, MBL production was screened by the Modified Hodge test and Combined Disk Test by using Imipenem-EDTA. Out of 91 isolates, MHT was positive in 84 isolates (92.3%) and MHT was positive in 12 isolates (13.18%). PCR detected MBL genes *bla_{VIM}*/*bla_{IMP}* in 20.2% (*bla_{VIM}*-16 and *bla_{IMP}*-1) among those positive isolates by phenotypic tests. This coincides with a high prevalence of *bla_{VIM}* among *Pseudomonas* isolates, a study by Amudhan M et al.¹⁴ The remaining 71 isolates that were MBL phenotypic test positive, were negative for both MBL genes (*bla_{VIM}*/*bla_{IMP}*) suggesting the presence of other MBL genes such as SIM-1, GIM-1, NDM-1 or SPM-1.

Despite the good performance of inhibitor-based methods (Combined disk test using IMP-EDTA) for the detection of MBL, false-positive results were found, hence this is not considered as a specific test. False positives may be due to EDTA which acts on the membrane of a bacterial cell and increases cell permeability. MHT also showed very low sensitivity. Hence the results of the MBL phenotypic tests must be interpreted cautiously.

The overall *bla_{VIM}*/*bla_{IMP}* production among study isolate was 20.2% among them, *bla_{VIM}* was found in 16 isolates whereas *bla_{IMP}* was found in one isolate. In Asia MBL genes, *bla_{VIM}* and *bla_{IMP}* are prevalent and *bla_{IMP}* is found in Japan, Korea, China, Taiwan and Iran.^{15–17}

The prevalence of MBL genes in India ranges from 7–65% among *P. aeruginosa*. In a study from India showed, the rate of MBL production was 24.5% among 61 *P. aeruginosa* isolates and *bla_{VIM}* was the most common. Another study from India also reported *bla_{VIM}*-2 from *P. aeruginosa*.¹⁸ In a nationwide survey conducted to characterize 301 MBL producing *Pseudomonas* species in 10 medical centers from India, the MBL genes were detected in 18.9% isolates.¹⁹ There are fewer data available on the prevalence and distribution of MBL among Indian isolates.

In this study, MBL phenotypic tests were positive in 92.3% isolates and among them, 20.2% isolates were carrying *bla_{VIM}*/*bla_{IMP}* genes indicating carbapenemase production. So, early detection of MBL production in Carbapenem-resistant *Pseudomonas aeruginosa* will not only help in treating the infections caused by them adequately and also help in preventing the spread of multidrug resistance to other Gram-negative strains. Therefore, all clinical isolates that are resistant to carbapenem must be screened for MBL production by using simple phenotypic tests and confirmed by the MBL Epsilometer test (E-test) or by PCR if possible.

To conclude, carbapenem resistance in *P. aeruginosa* is chiefly mediated by Metallo-beta-lactamase production.

Among the two phenotypic tests performed in this study, CDT was more sensitive compared to the Modified Hodge Test in the screening of MBL production. Genotypically, the common MBL gene -found was *bla_{VIM}* compared to *bla_{IMP}*. Therefore, screening for MBL production in microbiology laboratories is crucial for optimal treatment of patients, particularly hospitalized patients and also to prevent the possible spread of resistance to other Gram-negative organisms because of their broad-spectrum drug resistance which creates a therapeutic challenge to clinicians. Finally, to understand the epidemiology, there is a need for genetic analysis and also typing of Metallo-β-lactamase enzymes.

5. Source of Funding

None.

6. Conflict of Interest

None.

References

1. Singh SP, Shariff M, Barua T, Thukral SS. Comparative evaluation of phenotypic tests for identification of Metallo beta-lactamases producing clinical isolates of *Pseudomonas aeruginosa*. *Indian J Med Res*. 2009;129:713–5.
2. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? *Curr Opin Microbiol*. 2000;3(5):489–95.
3. Manoharan A, Chatterjee S, Mathai D. Detection and characterization of metallo beta lactamases producing *Pseudomonas aeruginosa*. *Indian J Med Microbiol*. 2010;28(3):241.
4. Watanabe M, Iyobe S, Inoue M, Mitsunashi S. Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 1991;35(1):147–51.
5. Pitout JDD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of *Pseudomonas aeruginosa* Producing Metallo-β-Lactamases in a Large Centralized Laboratory. *J Clin Microbiol*. 2005;43(7):3129–35.
6. Brahmadathan KN, Gladstone P, Rajendran P. Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units. *Indian J Med Microbiol*. 2005;23(3):189.
7. Poirel L, Nordmann P. Acquired Carbapenem-Hydrolyzing Beta-Lactamases and their Genetic Support. *Curr Pharm Biotechnol*. 2002;3(2):117–27.
8. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. *Clin Microbiol Infect*. 2002;8(6):321–31.
9. Sadari H, Karimi Z, Owlia P, Bahar MA, Rad SM. Phenotypic detection of metallo-beta-lactamase producing *Pseudomonas aeruginosa* strains isolated from burned patients. *Iran J Pathol*. 2008;3:20–4.
10. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol*. 2002;40(10):3798–3801.
11. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge Test and the Imipenem-EDTA Double-Disk Synergy Test for Differentiating Metallo-β-Lactamase-Producing Isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol*. 2003;41(10):4623–9.
12. Sheikh AF, Rostami S, Jolodar A, Tabatabaiefar MA, Khorvash F, Saki A, et al. Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant *Pseudomonas aeruginosa*. *Jundishapur J*

- Microbiol.* 2014;7(8). doi:10.5812/ijm.12289.
13. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20-U. Wayne, PA: CLSI; 2018.
 14. Amudhan MS, Sekar U, Kamalanathan A, Balaraman S. blaIMP and blaVIM mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India. *J Infect Dev Ctries.* 2012;6(11):757–62.
 15. Dong F, Xu X, Song WLP, Yu S, Yang Y. Characterization of multidrug-resistant and Metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from a pediatric clinic in China. *Chin Med J.* 2008;121(17):1611–6.
 16. Peymani A, Nahaei MR, Farajnia S, Hasani A, Mirsalehian, Sohrabi N, et al. High prevalence of Metallo- β lactamase- producing Acinetobacter baumannii in a teaching hospital in Tabriz, Iran. *Jpn J Infect Dis.* 2011;64:69–71.
 17. Franco MRG, Caiiffa-Filho HH, Burattini MN, Rossi F. Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. *Clinics.* 2010;65(9):825–9.
 18. Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR. blaVIM-2-Harboring Integrins Isolated in India, Russia, and the United States Arise from an Ancestral Class 1 Integron Predating the Formation of the 3' Conserved Sequence. *Antimicrob Agents Chemother.* 2007;51(7):2636–8.
 19. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem Resistance among Pseudomonas aeruginosa Strains

from India: Evidence for Nationwide Endemicity of Multiple Metallo- β -Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly Characterized VIM-18). *Antimicrob Agents Chemother.* 2009;53(3):1225–7.

Author biography

Ashwini Sondakar Senior Resident

Sneha K Chunchanur Assistant Professor

Ambica Rangaiah Professor and Head

Sathyanarayan Muthur Shankar Assistant Professor

Cite this article: Sondakar A, Chunchanur SK, Rangaiah A, Shankar SM. Molecular characterization of metallo-beta-lactamase producers among carbapenem resistant Pseudomonas aeruginosa isolated from cases of hospital acquired infections in a tertiary care hospital, Bengaluru. *Indian J Microbiol Res* 2020;7(2):212-217.